REGENXBIO (RGNX) IPO Prices In-Line at $22
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
REGENXBIO Announces Pricing of Initial Public Offering
September 16, 2015 8:30 PM EDTROCKVILLE, Md., Sept. 16, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. ("REGENXBIO"), a leading biotechnology company in gene therapy, today announced the pricing of its initial public offering of 6,300,000 shares of its common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions. In addition, REGENXBIO granted the underwriters a 30-day option to purchase up to an additional 945,000 shares of its common stock at the same price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on September 17, 2015 under the ticker symbol "RGNX."
Morgan Stanley and BofA Merrill Lynch are acting as active joint... More



